SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-056937
Filing Date
2024-03-04
Accepted
2024-03-04 08:15:54
Documents
16
Period of Report
2024-03-04
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d791106d8k.htm   iXBRL 8-K 26736
2 EX-99.1 d791106dex991.htm EX-99.1 9921
6 GRAPHIC g791106g0302040558021.jpg GRAPHIC 7597
  Complete submission text file 0001193125-24-056937.txt   177996

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA acrv-20240304.xsd EX-101.SCH 2838
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE acrv-20240304_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acrv-20240304_pre.xml EX-101.PRE 11699
17 EXTRACTED XBRL INSTANCE DOCUMENT d791106d8k_htm.xml XML 3758
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Filer) CIK: 0001781174 (see all company filings)

IRS No.: 825125532 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41551 | Film No.: 24712918
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)